Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.45 USD
+0.27 (1.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.46 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGEM 16.45 +0.27(1.67%)
Will CGEM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Checking Into Cullinan Therapeutics
Cullinan Management’s Zipalertinib Shows Lung Cancer Trial Promise
TD Cowen Sticks to Its Buy Rating for Cullinan Management (CGEM)
Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)
Analysts’ Top Healthcare Picks: Autolus Therapeutics (AUTL), Affimed (AFMD)